Search

Home > New FDA Approvals > 047 - Nucala (mepolizumab) for eosinophilic granulomatosis with polyangiitis; sNDA for OMIDRIA® for use in pediatric patients; FDA warns companies for promoting alternatives to street drugs


	Podcast:		New FDA Approvals
	Episode:		047 - Nucala (mepolizumab) for eosinophilic granulomatosis with polyangiitis; sNDA for OMIDRIA® for use in pediatric patients; FDA warns companies for promoting alternatives to street drugs
	Category:		Science & Medicine
	Duration:		00:10:02
	Publish Date:		2017-12-13 07:00:00
	Description:		December 13, 2017 0:30 - FDA approves Nucala (mepolizumab) for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm588594.htm 3:13 Omeros Corporation Announces FDA Approval of OMIDRIA® for Use in Pediatric Patients http://investor.omeros.com/phoenix.zhtml?c=219263&p=irol-newsArticle_Print&ID=2322260 4:17 FDA warns companies for promoting alternatives to street drugs https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm588585.htm ==== NASCENT MEDICAL Nascent Medical, LLC, has a team of over 100 PhD-/MD-level writers who can write about any medical, scientific or technical topic. They do the following types of writing, including but not limited to: -Video and virtual reality script writing -eLearning scripts -Medical education -Webinar slide creation -Manuscripts -Slidesets -Manuscripts -Press releases -Blog posts -Annual reports -Proposals -White papers -Web content -Posters -Sales training materials contact info@nascentmc.com ==== contact Emma NIchols, PhD, if you’d like to be on the upcoming AI in Medicine Podcast info@scimedly.com
	Total Play:		0